StockDriftsStockDriftsTop 5 SymBiosis Capital Partners, LLC Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| EVMN | Evommune, Inc. | 55.8% | 1.28M | $29.4M | +0.00%(+0) | $17.12(-24.30%) | 2026-03-31 | |
| IVA | Inventiva S.A. | 24.76% | 2.35M | $13.1M | -9.46%(-246.00K) | $5.22(-25.10%) | 2026-03-31 | |
| WVE | Wave Life Sciences Ltd. | 10.3% | 750.0K | $5.4M | new | $12.13(-48.37%) | 2026-03-31 | |
| RANI | Rani Therapeutics Holdings, Inc. | 5.11% | 3.67M | $2.7M | -41.78%(-2.63M) | $0.93(-16.65%) | 2026-03-31 | |
| CLNN | Clene Nanomedicine Inc. | 4.03% | 431.1K | $2.1M | -44.05%(-339.40K) | $5.95(+2.52%) | 2026-03-31 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative | Since First Filing (1 quarter) |
|---|---|---|---|---|---|
| Top 20 Holdings Weighted | — | — | — | — | -14.79% |
| Top 20 Holdings Unweighted | — | — | — | — | -22.95% |
SymBiosis Capital Partners, LLC reports $52.77M in US-listed equity holdings across 6 positions in its most recent 13F filing. Its largest disclosed positions are EVMN (55.8%), IVA (24.8%) and WVE (10.3%). The top 20 holdings account for 100% of reported assets. Its disclosed equity book has returned -14.79% cumulatively over 1 quarter. Figures reflect the Q1 2026 filing.
Portfolio changes
Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.
Sign up free to track SymBiosis Capital Partners, LLC, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from SymBiosis Capital Partners, LLC’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 2006045). View SymBiosis Capital Partners, LLC’s 13F filings on SEC